Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | ENPP2 | Q13822 | 8/20 | 0.52 |
| ▸ | CD40 | P25942 | 1/20 | 0.50 |
| ▸ | CD40LG | P29965 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.47 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | DNASE1L3 | Q13609 | 1/20 | 0.44 |
| ▸ | CASP6 | P55212 | 2/20 | 0.44 |
| ▸ | NSD2 | O96028 | 1/20 | 0.44 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.44 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.44 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.44 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL105571 | 0.98 | CYP1A2 (0.51) | CYP1A2ALDH1A1HIF1AMEN1THRB | |
| SCHEMBL3215642 | 0.88 | CYP1A2 (0.62) | CYP1A2ALDH1A1HIF1AMEN1THRB | |
| SCHEMBL3302890 | 0.87 | CYP1A2 (0.51) | CYP1A2ALDH1A1HIF1AMEN1THRB | |
| Water SCHEMBL22500691 | 0.87 | CYP1A2 (0.60) | CYP1A2ALDH1A1HIF1AMEN1THRB | |
| SCHEMBL1882514 | 0.87 | CYP1A2 (0.60) | CYP1A2ALDH1A1HIF1AMEN1THRB | |
| SCHEMBL2527187 | 0.87 | CYP1A2 (0.60) | CYP1A2ALDH1A1HIF1AMEN1THRB | |
| Water SCHEMBL7943499 | 0.85 | CYP1A2 (0.59) | CYP1A2ALDH1A1HIF1AMEN1THRB | |
| SCHEMBL5921946 | 0.83 | MPL (0.50) | CYP1A2ALDH1A1HIF1AMEN1THRB | |
| SCHEMBL4280353 | 0.82 | ALDH1A1 (0.54) | CYP1A2ALDH1A1HIF1AMEN1THRB | |
| SCHEMBL3203561 | 0.82 | ALDH1A1 (0.54) | CYP1A2ALDH1A1HIF1AMEN1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130028942-A1 | AEROSOLIZED NITRITE AND NITRIC OXIDE-DONATING COMPOUNDS AND USES THEREOF | AIRES PHARMACEUTICALS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| EP-2237788-A2 | AEROSOLIZED NITRITE AND NITRIC OXIDE - DONATING COMPOUNDS AND USES THEREOF | Aires Pharmaceuticals, Inc. (US) | 2010-10-13 | — | — | EP | disclosed |
| US-20090196930-A1 | AEROSOLIZED NITRITE AND NITRIC OXIDE -DONATING COMPOUNDS AND USES THEREOF | AIRES PHARMACEUTICALS, INC. (US) | 2009-08-06 | — | — | US | disclosed |
| WO-2009086470-A2 | AEROSOLIZED NITRITE AND NITRIC OXIDE - DONATING COMPOUNDS AND USES THEREOF | AIRES PHARMACEUTICALS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130028942-A1 | AEROSOLIZED NITRITE AND NITRIC OXIDE-DONATING COMPOUNDS AND USES THEREOF | NOS1, NOS2, NOS3 | CYP1A2 596/4885ALDH1A1 351/4885HIF1A 928/4885 |
| US-20090196930-A1 | AEROSOLIZED NITRITE AND NITRIC OXIDE -DONATING COMPOUNDS AND USES THEREOF | NOS1, NOS2, NOS3 | CYP1A2 596/4885ALDH1A1 351/4885HIF1A 928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.